We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Immunoassay Evaluated for Cardiac Troponin

By LabMedica International staff writers
Posted on 05 Feb 2013
Print article
The analytical performance of an immunoenzymometric assay for the cardiac troponin (cTnI) has been appraised and compared with other methods.

The test is a two-site immunoenzymometric assay, which uses a combination of two monoclonal antibodies, respectively directed to 41–49 and 87–91 amino acids of the cTnI peptide chain, and the ternary troponin ITC complex as a calibration antigen.

Scientists at the Fondazione Toscana G. Monasterio (Pisa, Italy) evaluated the assay in 452 healthy individuals of which 326 were males and 126 were female. The median age was 45 years with a range between 17 to 76 years. The study participants were recruited from laboratory staff, blood donors, or voluntary subjects, included in screening programs for preventive medicine.

The immunoenzymometric assay for the cTnI evaluated in the study was the Tosoh ST AIA-PACK cTnI 3rd-Generation, and it uses the automated AIA-2000 platform (Tosoh Corporation, Tokyo, Japan). The third-generation AIA-Pack assay for cTnI showed an improved analytical sensitivity and reproducibility, especially at very low cTnI concentrations compared to the previous second-generation AIA-Pack assay. The values of the third-generation assay were a limit of detection (LoD) at 8.7 ng/L and the limit of quantitation (LoQ) at 100 ng/L. The LoD and 10% LoQ values of the second-generation assay reported previously were 38 ng/L and 130 ng/L, respectively.

The third-generation AIA-Pack Tosoh assay for cTnI showed a very close agreement throughout all the working range with the Access AccuTnI Beckman–Coulter method (Beckman Coulter, Inc.; Fullerton, CA, USA). Close concordance was also demonstrated between the cTnI measured by Tosoh methods and those of cTnT measured with ECLIA Roche method (Roche Diagnostics, Mannheim, Germany). The authors concluded that their results imply that the third generation AIA-Pack assay is suitable for the clinical evaluation of patients with cardiac diseases. The study was published in the January 2013 issue of the journal Clinica Chimica Acta.

Related Links:
Fondazione Toscana G. Monasterio
Beckman Coulter Inc.
Roche Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more